Bexagliflozin API CAS 1118567-05-7

Bexagliflozin API is a regulatory substance for adult metabolic disorders, mainly to balance blood glucose. It is particularly suitable for daily health management of people with type 2 glucose metabolism disorders, and its unique mechanism and comprehensive health benefits make it an important choice for their blood glucose control. Its core mechanism is inhibiting renal sodium-glucose cotransporter 2, reducing renal tubular glucose reabsorption and allowing excess glucose to be excreted naturally through urine to stably regulate blood glucose. This action is independent of insulin function; even with insufficient insulin secretion, it can still work stably, applicable to more people with different condition levels. Compared with similar substances, bexagliflozin has obvious advantages: it effectively regulates both fasting and postprandial blood glucose, especially excelling in postprandial control, preventing large fluctuations, helping maintain blood glucose in a reasonable and stable range and reducing its adverse effects on the body.

During use, note common physical responses: higher urine glucose levels may make the urinary and reproductive systems more susceptible to infections by fostering bacterial growth, so users should practice good personal hygiene and drink ample water to boost metabolism and lower infection risks. Besides, excessive glucose excretion in urine may trigger osmotic diuresis symptoms like frequent urination and thirst; some people may have mild hypotension, which usually eases on its own with timely fluid intake and avoiding overfatigue, requiring no undue worry.